Vitamin markets sees upward price pressure

But still quite conservative and careful at the buyer side. Some attempts to increase price for vitamin B1, B6, B3, B5 and B2. No effect so far. Lower priced/kg vitamins are impacted somewhat by higher container freight rates ex China.

In partnership with Feed Additive Prices

Vitamin E 50%

The market sentiment is firmer and the market shows decent buying activity in several regions at the moment. Delays in shipments, price increase announcements, announced plant maintenance, low stock levels, and decent consumption have led to a firmer market. Prices have moved up a bit in most regions, but it is still conservative as there are still doubts as to how long this firmer period can and will last. It did trigger Q3 buying as prices are still relatively low. Q2 is contracted and a large portion of Q3 is being contracted at the moment as well in order to secure supply.

Vitamin A 1000

Several potential market disruptions are being communicated like price increases, reduction in production output, maintenance periods, and supply delays. But so far the price is not moving at all and buyers are not reacting really to any of these communications. Prices are stable in most regions. Neither a price decline nor a price increase is seen. The market is quiet. Most of Q2 has been contracted and a portion of Q3 as well.

Vitamin D3 500

Prices fob China have gone up lately and there is a strong desire by manufacturers and suppliers to increase prices and move away from the relatively low price level. But as with many vitamins, it is not that easy and buyers are not tempted to take long-term contracts as they do not see any structural bullish factors. This has led to stable prices in most regions so far, at a low price level. The market feels quiet, despite the delays ex China and higher container freight costs. Q2 is contracted, and in some cases a portion of Q3.

Vitamin B2 80%

Again, there have been some attempts by suppliers to increase prices, but so far there has been no reaction from the market. In general, the vitamin B2 market remains quiet and stable. Prices in Asia are still relatively low, while prices in Europe and the US are higher. Most of Q2 is contracted and bits and pieces of Q3 as well.

D-Calpan

Suppliers are trying to increase prices for new demand and container price increases are potentially leading to firmer prices as well, although that impact is relatively limited on the total price/kg. Despite that, prices remain stable in most regions at a low level as supply in general is ample and suppliers are keen to maintain market share and move stock. Already a decent cover ahead is taken for Q2. Q3 is still mostly uncovered.

Vitamin B3

Most suppliers have stopped reducing prices further, as that did not trigger additional sales. Demand is still said to be sluggish, so a price increase in the short term is also not very likely. In general, the market feels quiet and prices are mostly stable at a relatively low level. Availability seems to be OK in most regions. There was already some cover taken into Q2 and even early Q3 some time ago when prices stabilised at a low level.

Biotin

There have been some attempts by manufacturers to increase prices, but it did not work. Supply is ample and long-term contracts have been concluded and/or pending. The market is quiet and even slightly lower prices were seen again for both biotin pure or the lower 2% content material. Prices remain historically low. Most of Q2 is contracted and some of Q3 is as well. In some cases, buyers took long-term contracts well into late 2024.

Vitamin C 35% mono

Even though some manufacturers have indicated to reduce their production output, the market sentiment has turned a bit weak over the past few weeks. No major changes are seen, but in some regions, vitamin C prices have come down a bit and demand is sluggish. Prices are still at a higher level though, compared to a year ago. There are still long-term contracts in place that were concluded at the previous low price levels and carry well into 2024. Q2 is largely contracted and in some cases, a large portion of 2024 as well.